By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on AbbVie (ABBV) and Realty Income (O). While AbbVie's dividend growth is uncertain due to Humira's patent cliff and pipeline dependence, Realty Income's high occupancy and fixed-rate debt provide some dividend safety, but reinvestment risk and potential multiple compression in a high-rate environment are significant concerns.
Risk: Reinvestment risk for Realty Income in a high-rate environment and potential slowdown in AbbVie's dividend growth due to Humira's patent cliff.
Opportunity: AbbVie's successful navigation of the Humira patent cliff and Realty Income's high occupancy and fixed-rate debt.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
AbbVie is a Dividend King that has proven its ability to adapt.
Realty Income is the ultimate monthly income play.
Should investors really "sell in May and go away"? Not if you're seeking income. A stock you no longer own won't pay you any dividends.
If you're looking for reliable income in May, several dividend stocks should be attractive. Here are two that offer especially reliable income.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
AbbVie's (NYSE: ABBV) board of directors declared a quarterly cash dividend of $1.73 per share in February. This dividend is payable on May 15, 2026. There's one catch, though: To receive this dividend, you must have owned AbbVie shares at the close of business on April 15, 2026.
Even if you missed the cut-off for enjoying income from AbbVie this month, it's the kind of stock to buy for steady dividends going forward. AbbVie is a member of the Dividend Kings, a group of stocks that have increased their dividends for at least 50 consecutive years. Including the time it was part of Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for an impressive 54 years in a row.
AbbVie's dividend increases have more than kept up with inflation. Over the last five years, the big drugmaker has grown its dividend payout by 33%. Since being spun off from Abbott in 2013, AbbVie's dividend has skyrocketed more than 332%. Its forward dividend yield now stands above 3.3%, which is below its historical average because the pharma stock has delivered solid gains.
The key to AbbVie's sterling dividend track record is its strong underlying business. For years, that business was primarily supported by Humira, which reigned as the world's top-selling drug for a while. Humira lost U.S. patent exclusivity in 2023, but AbbVie didn't skip a beat. Thanks to strategic acquisitions and investments in internal research and development, the company successfully navigated the patent cliff and quickly returned to growth.
AbbVie has proven its ability to adapt. Today, the company's growth prospects look bright. Sales for Humira's two successors, Skyrizi and Rinvoq, are soaring. AbbVie's neuroscience portfolio is rocking along, led by Vraylar and Botox. Cancer drugs Elahere and Epkinly are gaining momentum. The drugmaker's pipeline features around 60 programs in mid- or late-stage clinical development.
Want a great monthly dividend stock? Realty Income (NYSE: O) could be the ultimately every-month income play. It even trademarked the name, "The Monthly Dividend Company."
Real estate investment trusts (REITs) must return at least 90% of their income to shareholders as dividends to be exempt from federal income taxes. Realty Income has had plenty of income to return since going public in 1994. The company has paid a dividend for 670 consecutive quarters and has increased its dividend for 31 consecutive years. Its forward dividend yield currently tops 5%.
As with AbbVie, Realty Income's dividend is highly reliable because its business generates steady cash flow. The REIT owns over 15,500 properties across all 50 U.S. states, the U.K., and eight European countries. Its 1,761 tenants represent 92 industries. Roughly 91% of Realty Income's portfolio clients operate discount, non-discretionary, or service-oriented retail businesses that are resilient during both positive and negative economic cycles.
The company's total occupancy rate is a strong 98.9%. Realty Income has consistently maintained an occupancy rate of at least 96.6% every year since 2000, a period that included the Great Recession of 2007 through 2009 and the COVID-19 pandemic of 2020 through 2022. Its historical median occupancy rate of 98.3% is well above the industry median of 94.4%.
Realty Income's growth prospects are also encouraging. Its total addressable market is an estimated $13 trillion. Around $8.5 trillion of this opportunity is in Europe, where the market is highly fragmented. The REIT's growth potential makes it highly likely that juicy dividends will continue to flow each month, as they have for decades.
Before you buy stock in Realty Income, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Realty Income wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $490,864! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,789!
Now, it’s worth noting Stock Advisor’s total average return is 963% — a market-crushing outperformance compared to 201% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 6, 2026. *
Keith Speights has positions in AbbVie and Realty Income. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Realty Income. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The reliability of these dividends is currently priced to perfection, leaving little margin for error if interest rates remain elevated or if AbbVie's pipeline growth misses consensus estimates."
While ABBV and O are classic income staples, the article ignores the macro headwinds of a 'higher-for-longer' rate environment. For Realty Income (O), the cost of capital is the primary threat; as a REIT, they rely on debt to fund acquisitions, and their spread over the 10-year Treasury is currently compressed, limiting FFO (Funds From Operations) growth. AbbVie (ABBV) is successfully navigating the Humira patent cliff, but trading at roughly 14x forward earnings, it is no longer the 'value' play it was two years ago. Investors are paying a premium for that dividend yield, and any regulatory pressure on drug pricing could cause a multiple contraction that wipes out several years of dividend gains.
If you are a long-term income investor, these companies provide essential, non-discretionary cash flows that outperform during market volatility, making their premium valuation a justified 'safety tax.'
"ABBV's post-Humira immunology growth and pipeline depth make it a superior Dividend King pick over REITs like O in a high-rate environment."
AbbVie (ABBV) deserves credit for navigating the Humira patent cliff, with Skyrizi and Rinvoq sales surging 47% and 62% YoY in Q1 2024 (per latest earnings, not article), driving 80bps EPS growth beat and maintaining a 3.4% yield on a 1.7x payout ratio. Realty Income (O) boasts 98.9% occupancy across resilient retail, but glosses over rising interest costs—debt maturities average SOFR+ spreads, pressuring AFFO amid 5.3% 10Y yields. Both reliable long-term, but article ignores high-rate headwinds compressing REIT multiples (O at 14x AFFO vs. 12x historical). Buy ABBV dips; hold O for income, not growth.
If biosimilar competition accelerates beyond expectations for Skyrizi/Rinvoq or if Realty Income's retail tenants face e-commerce secular erosion despite high occupancy, dividend safety erodes faster than historical resilience suggests.
"Both stocks offer real dividend reliability, but their current yields reflect fair compensation for their risks—there's no margin of safety for new buyers at today's prices."
This article is promotional fluff masquerading as analysis. Both stocks are legitimate dividend payers, but the piece omits critical context: ABBV trades at a 3.3% yield because the market has priced in Humira's cliff risk materializing faster than expected—Skyrizi and Rinvoq haven't yet proven they can fully replace $20B+ in lost revenue. Realty Income's 5% yield looks attractive until you note that REITs have underperformed since 2022 as rates rose; a 5% yield in a 4.5% rate environment leaves little margin for error if cap rates compress further or occupancy slips. The article cherry-picks occupancy data (98.9% now) without addressing tenant credit quality or lease expiration cliffs. Both are mature, slow-growth vehicles—fine for retirees, but the framing as 'reliable income' obscures duration and reinvestment risk.
If you're genuinely seeking inflation-protected income, ABBV's 54-year dividend track record and recent 33% payout growth over five years actually does justify a premium to the broader market, and O's 670-quarter streak with 31 consecutive increases is genuinely rare and worth a modest valuation premium.
"Dividend reliability depends on cash flow growth in a high-rate, slower-growth environment, not on the calendar."
Two dividend stalwarts get spotlight for May: AbbVie and Realty Income promise steady cash flow and monthly income. The optimistic case ignores two big risks: (1) AbbVie's Humira patent cliff and pipeline-dependent growth could slow dividend growth if new drugs underperform; (2) Realty Income relies on high occupancy and rent collections, but a recession or rate shock could pressure tenants and refinancing costs, even with a broad, diversified portfolio. Also, the article glosses over valuation risk: a 5% forward yield may look attractive, but total return could lag if multiple expansion stalls. In short, income is real—but not guaranteed this year.
Humility: AbbVie's dividend growth hinges on pipeline performance; if Humira's legacy revenue declines more than expected, the payout could stall. Realty Income's rent upside may be constrained by higher cap rates and refinancing risk in a downturn.
"Realty Income faces a valuation reset as rising risk-free rates force a higher yield requirement, regardless of their operational occupancy."
Claude, you’re right about the dividend track record, but you’re ignoring the 'bond proxy' trap. When Treasury yields hit 4.5%, investors dump REITs like Realty Income not just for credit risk, but because the risk-free rate makes their 5% yield uncompetitive on a risk-adjusted basis. If we see a 'higher-for-longer' scenario, O’s multiple will compress further to push the yield closer to 6%. It’s not just a tenant credit issue; it’s a valuation reset.
"Realty Income's long-dated fixed-rate debt significantly reduces near-term interest rate risk to AFFO and dividends."
Gemini and Grok, you're both overemphasizing short-term rate pain for Realty Income (O)—their debt is 99.1% fixed-rate with a 9.8-year weighted average maturity (Q1 2024 10-Q), so AFFO erosion from refinancing is muted until 2030+. This maturity wall insulates dividends better than retail peers. Panel misses the rebound if Fed cuts by year-end; O's 5% yield becomes a steal at current 14x AFFO.
"Fixed-rate debt maturity provides tactical cover until 2030, but masks structural reinvestment risk that could compress dividend growth when refinancing begins."
Grok's 99.1% fixed-rate debt maturity wall is real, but misses the reinvestment cliff: O's AFFO compounds only if they redeploy maturing debt at similar rates. If 2030+ refinancing happens at 5%+ (vs. today's 3-4% embedded cost), AFFO growth stalls even if occupancy holds. Fed rate cuts help valuation, not cash flow—that's a multiple play, not a dividend safety case. Claude's tenant credit quality concern remains unaddressed.
"In a persistently high-rate regime, Realty Income's long refinancing horizon and potential cap-rate expansion could compress AFFO growth and push the stock's multiple toward the low-teens, not 14x, with yields rising to ~5-6%."
Responding to Grok: fixed-rate debt and a long maturity wall help, but they don't cure reinvestment risk. If rates stay higher for longer, O must refinance after 2030 at ~5%+ and cap rates may expand, damping AFFO growth and pressuring multiples. The bullish thesis hinges on rare, benign refinancing and rate cuts; in a persistent high-rate regime, O could trade closer to 12x AFFO with yields near 5-6%, not 14x/5%.
The panel is divided on AbbVie (ABBV) and Realty Income (O). While AbbVie's dividend growth is uncertain due to Humira's patent cliff and pipeline dependence, Realty Income's high occupancy and fixed-rate debt provide some dividend safety, but reinvestment risk and potential multiple compression in a high-rate environment are significant concerns.
AbbVie's successful navigation of the Humira patent cliff and Realty Income's high occupancy and fixed-rate debt.
Reinvestment risk for Realty Income in a high-rate environment and potential slowdown in AbbVie's dividend growth due to Humira's patent cliff.